• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
5.71% $1.49

MESOBLAST LIMITED - Announcements

Market Cap $1.113B  ! watchlist Created with Sketch. Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD PatientsPRICE SENSITIVE27/03/19
MSB MSB Licensee Files For Skin Disease Marketing ApprovalPRICE SENSITIVE25/03/19
MSB Mesoblast Provides Half Year Results and Corporate UpdatePRICE SENSITIVE21/02/19
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE21/02/19
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
MSB MSB Draws US$15 Million From Existing FacilityPRICE SENSITIVE14/01/19
MSB P3 Trial of MSB's Cell Therapy in CHF Completes RecruitmentPRICE SENSITIVE07/01/19
MSB Response to ASX queryPRICE SENSITIVE05/12/18
MSB MSB Provides Q1 Financial Results and Operational HighlightsPRICE SENSITIVE16/11/18
MSB First Quarter Financial Results on Form 6-KPRICE SENSITIVE16/11/18
MSB LVAD Results Webcast PresentationPRICE SENSITIVE13/11/18
MSB LVAD Trial Results Provide Potential Regulatory PathwayPRICE SENSITIVE12/11/18
MSB Pause in TradingPRICE SENSITIVE12/11/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/18
MSB MSB Expands Partnership With JCR For Skin DiseasePRICE SENSITIVE24/10/18
MSB Completion of Tasly Transaction, and Appendix 3BPRICE SENSITIVE12/10/18
MSB Day 180 Survival Outcomes In aGvHD Phase 3 TrialPRICE SENSITIVE20/09/18
MSB Tasly Receives Approvals For Transaction With MSBPRICE SENSITIVE17/09/18
MSB Mesoblast Reports on Annual and Fourth Quarter ResultsPRICE SENSITIVE30/08/18
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/18
MSB UPDATE ON TASLY TRANSACTIONPRICE SENSITIVE29/08/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
MSB MSB Enters Into Cardiovascular Alliance For China With TaslyPRICE SENSITIVE17/07/18
MSB MSB Enters Into US$50M Financing With NovaQuest CapitalPRICE SENSITIVE02/07/18
MSB Key Day 100 Survival Results In P3 GvHD TrialPRICE SENSITIVE21/06/18
MSB Third Quarter Financial Results on Form 6-KPRICE SENSITIVE31/05/18
MSB Partnership For Allogeneic Cell-based Cancer ImmunotherapiesPRICE SENSITIVE29/05/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
MSB MSB Enters Into $75 Million Non-Dilutive Credit FacilityPRICE SENSITIVE07/03/18
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE28/02/18
MSB GVHD Day 28 Results PresentationPRICE SENSITIVE23/02/18
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD TrialPRICE SENSITIVE22/02/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
MSB Appendix 3B with prospectusPRICE SENSITIVE19/01/18
MSB Mesoblast Receives RMAT For LVAD Heart Failure PatientsPRICE SENSITIVE21/12/17
MSB Mesoblast's P3 GVHD Trial Completes EnrollmentPRICE SENSITIVE20/12/17
MSB Mesoblast Grants TiGenix License For Treatment of FistulaePRICE SENSITIVE15/12/17
MSB MSB Named Global Technology Leader In Cell Therapy IndustryPRICE SENSITIVE08/12/17
MSB Response to ASX Aware Letter QueryPRICE SENSITIVE17/11/17
MSB Mesoblast Provides Corporate Update and Q1 Financial ResultsPRICE SENSITIVE15/11/17
MSB First Quarter Results On Form 6KPRICE SENSITIVE15/11/17
MSB RA Phase 2 Trial Results Presented At ACR Annual MeetingPRICE SENSITIVE13/11/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
MSB End-Stage Heart Failure Trial Completes EnrollmentPRICE SENSITIVE28/09/17
MSB Mesoblast Corporate Updates at Healthcare ConferencesPRICE SENSITIVE25/09/17
MSB Retail Entitlement OfferPRICE SENSITIVE01/09/17
MSB Mesoblast Reports on Annual and Fourth Quarter ResultsPRICE SENSITIVE30/08/17
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/17
MSB Underwritten A$50.7M Raise Closes Institutional AllocationPRICE SENSITIVE29/08/17
MSB Fully Underwritten A$50.7 Million Entitlement OfferPRICE SENSITIVE25/08/17
MSB Trading HaltPRICE SENSITIVE25/08/17
MSB Potential For Accelerated Market Entry In Advanced CHFPRICE SENSITIVE23/08/17
MSB Positive Results of MSB Therapy in Osteoarthritis PublishedPRICE SENSITIVE16/08/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
MSB Mesoblast RA Results Presented At EULAR CongressPRICE SENSITIVE22/06/17
MSB MSB Provides Q3 Operational Highlights and Financial ResultsPRICE SENSITIVE25/05/17
MSB Third Quarter Financial Results On Form 6-KPRICE SENSITIVE25/05/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
MSB Successful Interim Analysis in Phase 3 Heart Failure TrialPRICE SENSITIVE10/04/17
MSB Mesoblast Receives A$3.7m From Aus Govt For R&DPRICE SENSITIVE06/04/17
MSB FDA Clears Heart Disease Trial At Boston Childrens HospitalPRICE SENSITIVE04/04/17
MSB Process Initiated For CHF P3 Interim AnalysisPRICE SENSITIVE31/03/17
MSB Mesoblast Raises US$40 MillionPRICE SENSITIVE27/03/17
MSB Durable Three Year Outcomes in Disc DiseasePRICE SENSITIVE15/03/17
MSB FDA Grants Mesoblast Fast Track Designation For GVHDPRICE SENSITIVE07/03/17
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE27/02/17
MSB Positive Nine Month RA Results For Mesoblast Cell TherapyPRICE SENSITIVE16/02/17
MSB Published Results Show MSB Cells Effective In RA ModelPRICE SENSITIVE13/02/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
MSB Mesoblast Director Recognized For Cardiovascular LeadershipPRICE SENSITIVE31/01/17
MSB Mesoblast And Mallinckrodt Enter Into AgreementPRICE SENSITIVE23/12/16
MSB MD Anderson and NIH Fund Trial Using Mesoblast TechnologiesPRICE SENSITIVE06/12/16
MSB Mesoblast Provides Corporate Update and Q1 Financial ResultsPRICE SENSITIVE15/11/16
MSB First Quarter Results On Form 6KPRICE SENSITIVE15/11/16
MSB Successful Interim Futility Analysis In P3 Trial for GVHDPRICE SENSITIVE14/11/16
MSB Appendix 4C - quarterly-MSB.AX PRICE SENSITIVE31/10/16
MSB MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX PRICE SENSITIVE12/10/16
MSB Mesoblast Phase 2 Diabetic Kidney Disease Results Published-MSB.AX PRICE SENSITIVE06/10/16
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX PRICE SENSITIVE28/08/16
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX PRICE SENSITIVE28/08/16
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX PRICE SENSITIVE25/08/16
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX PRICE SENSITIVE25/08/16
MSB MSB Strengthens US Patent Portfolio For Rheumatic Diseases-MSB.AX PRICE SENSITIVE17/08/16
MSB Mesoblast P2 Results Show Dose-Related Improvements In RA-MSB.AX PRICE SENSITIVE09/08/16
MSB MSB Back Pain Results Presented, Receive Best Science Award-MSB.AX PRICE SENSITIVE01/08/16
MSB Appendix 4C - quarterly-MSB.AX PRICE SENSITIVE29/07/16
MSB Update on Heart Failure Trial and Funding of Operations-MSB.AX PRICE SENSITIVE01/07/16
MSB Reinstatement to Official Quotation-MSB.AX PRICE SENSITIVE14/06/16
MSB Update on Global Heart Failure Program-MSB.AX PRICE SENSITIVE14/06/16
MSB Suspension from Official Quotation-MSB.AX PRICE SENSITIVE03/06/16
MSB Trading Halt-MSB.AX PRICE SENSITIVE01/06/16
MSB Mesoblast Receives $6.2m From Aus Govt For R&D-MSB.AX PRICE SENSITIVE20/05/16
MSB Mesoblast Provides Q3 Financial Results and Corporate Update-MSB.AX PRICE SENSITIVE10/05/16
MSB Third Quarter Financial Results On Form 6-K-MSB.AX PRICE SENSITIVE10/05/16
MSB Appendix 4C - quarterly-MSB.AX PRICE SENSITIVE28/04/16
MSB Mesoblast Cells Show Disease Modifying Effects on Knee OAPRICE SENSITIVE01/04/16
MSB Key US Patent Granted For Treatment Of Rheumatoid ArthritisPRICE SENSITIVE24/03/16
MSB GVHD Product Launched In JapanPRICE SENSITIVE24/02/16
MSB Increased Survival Using MSB Cells In Children With aGVHDPRICE SENSITIVE22/02/16
MSB Half Yearly Report and Accounts (including Appendix 4D)PRICE SENSITIVE17/02/16
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
27/03/19PRICE SENSITIVE
MSB MSB Licensee Files For Skin Disease Marketing Approval
25/03/19PRICE SENSITIVE
MSB Mesoblast Provides Half Year Results and Corporate Update
21/02/19PRICE SENSITIVE
MSB Half Year Report and Accounts (including Appendix 4D)
21/02/19PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
MSB MSB Draws US$15 Million From Existing Facility
14/01/19PRICE SENSITIVE
MSB P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
07/01/19PRICE SENSITIVE
MSB Response to ASX query
05/12/18PRICE SENSITIVE
MSB MSB Provides Q1 Financial Results and Operational Highlights
16/11/18PRICE SENSITIVE
MSB First Quarter Financial Results on Form 6-K
16/11/18PRICE SENSITIVE
MSB LVAD Results Webcast Presentation
13/11/18PRICE SENSITIVE
MSB LVAD Trial Results Provide Potential Regulatory Pathway
12/11/18PRICE SENSITIVE
MSB Pause in Trading
12/11/18PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/10/18PRICE SENSITIVE
MSB MSB Expands Partnership With JCR For Skin Disease
24/10/18PRICE SENSITIVE
MSB Completion of Tasly Transaction, and Appendix 3B
12/10/18PRICE SENSITIVE
MSB Day 180 Survival Outcomes In aGvHD Phase 3 Trial
20/09/18PRICE SENSITIVE
MSB Tasly Receives Approvals For Transaction With MSB
17/09/18PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/18PRICE SENSITIVE
MSB Preliminary Final Report including Appendix 4E
30/08/18PRICE SENSITIVE
MSB UPDATE ON TASLY TRANSACTION
29/08/18PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
MSB MSB Enters Into Cardiovascular Alliance For China With Tasly
17/07/18PRICE SENSITIVE
MSB MSB Enters Into US$50M Financing With NovaQuest Capital
02/07/18PRICE SENSITIVE
MSB Key Day 100 Survival Results In P3 GvHD Trial
21/06/18PRICE SENSITIVE
MSB Third Quarter Financial Results on Form 6-K
31/05/18PRICE SENSITIVE
MSB Partnership For Allogeneic Cell-based Cancer Immunotherapies
29/05/18PRICE SENSITIVE
MSB Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
MSB MSB Enters Into $75 Million Non-Dilutive Credit Facility
07/03/18PRICE SENSITIVE
MSB Half Year Report and Accounts (including Appendix 4D)
28/02/18PRICE SENSITIVE
MSB GVHD Day 28 Results Presentation
23/02/18PRICE SENSITIVE
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
22/02/18PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
MSB Appendix 3B with prospectus
19/01/18PRICE SENSITIVE
MSB Mesoblast Receives RMAT For LVAD Heart Failure Patients
21/12/17PRICE SENSITIVE
MSB Mesoblast's P3 GVHD Trial Completes Enrollment
20/12/17PRICE SENSITIVE
MSB Mesoblast Grants TiGenix License For Treatment of Fistulae
15/12/17PRICE SENSITIVE
MSB MSB Named Global Technology Leader In Cell Therapy Industry
08/12/17PRICE SENSITIVE
MSB Response to ASX Aware Letter Query
17/11/17PRICE SENSITIVE
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/17PRICE SENSITIVE
MSB First Quarter Results On Form 6K
15/11/17PRICE SENSITIVE
MSB RA Phase 2 Trial Results Presented At ACR Annual Meeting
13/11/17PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
MSB End-Stage Heart Failure Trial Completes Enrollment
28/09/17PRICE SENSITIVE
MSB Mesoblast Corporate Updates at Healthcare Conferences
25/09/17PRICE SENSITIVE
MSB Retail Entitlement Offer
01/09/17PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/17PRICE SENSITIVE
MSB Preliminary Final Report including Appendix 4E
30/08/17PRICE SENSITIVE
MSB Underwritten A$50.7M Raise Closes Institutional Allocation
29/08/17PRICE SENSITIVE
MSB Fully Underwritten A$50.7 Million Entitlement Offer
25/08/17PRICE SENSITIVE
MSB Trading Halt
25/08/17PRICE SENSITIVE
MSB Potential For Accelerated Market Entry In Advanced CHF
23/08/17PRICE SENSITIVE
MSB Positive Results of MSB Therapy in Osteoarthritis Published
16/08/17PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
MSB Mesoblast RA Results Presented At EULAR Congress
22/06/17PRICE SENSITIVE
MSB MSB Provides Q3 Operational Highlights and Financial Results
25/05/17PRICE SENSITIVE
MSB Third Quarter Financial Results On Form 6-K
25/05/17PRICE SENSITIVE
MSB Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
MSB Successful Interim Analysis in Phase 3 Heart Failure Trial
10/04/17PRICE SENSITIVE
MSB Mesoblast Receives A$3.7m From Aus Govt For R&D
06/04/17PRICE SENSITIVE
MSB FDA Clears Heart Disease Trial At Boston Childrens Hospital
04/04/17PRICE SENSITIVE
MSB Process Initiated For CHF P3 Interim Analysis
31/03/17PRICE SENSITIVE
MSB Mesoblast Raises US$40 Million
27/03/17PRICE SENSITIVE
MSB Durable Three Year Outcomes in Disc Disease
15/03/17PRICE SENSITIVE
MSB FDA Grants Mesoblast Fast Track Designation For GVHD
07/03/17PRICE SENSITIVE
MSB Half Year Report and Accounts (including Appendix 4D)
27/02/17PRICE SENSITIVE
MSB Positive Nine Month RA Results For Mesoblast Cell Therapy
16/02/17PRICE SENSITIVE
MSB Published Results Show MSB Cells Effective In RA Model
13/02/17PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
MSB Mesoblast Director Recognized For Cardiovascular Leadership
31/01/17PRICE SENSITIVE
MSB Mesoblast And Mallinckrodt Enter Into Agreement
23/12/16PRICE SENSITIVE
MSB MD Anderson and NIH Fund Trial Using Mesoblast Technologies
06/12/16PRICE SENSITIVE
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/16PRICE SENSITIVE
MSB First Quarter Results On Form 6K
15/11/16PRICE SENSITIVE
MSB Successful Interim Futility Analysis In P3 Trial for GVHD
14/11/16PRICE SENSITIVE
MSB Appendix 4C - quarterly-MSB.AX
31/10/16PRICE SENSITIVE
MSB MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX
12/10/16PRICE SENSITIVE
MSB Mesoblast Phase 2 Diabetic Kidney Disease Results Published-MSB.AX
06/10/16PRICE SENSITIVE
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX
28/08/16PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX
28/08/16PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX
25/08/16PRICE SENSITIVE
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX
25/08/16PRICE SENSITIVE
MSB MSB Strengthens US Patent Portfolio For Rheumatic Diseases-MSB.AX
17/08/16PRICE SENSITIVE
MSB Mesoblast P2 Results Show Dose-Related Improvements In RA-MSB.AX
09/08/16PRICE SENSITIVE
MSB MSB Back Pain Results Presented, Receive Best Science Award-MSB.AX
01/08/16PRICE SENSITIVE
MSB Appendix 4C - quarterly-MSB.AX
29/07/16PRICE SENSITIVE
MSB Update on Heart Failure Trial and Funding of Operations-MSB.AX
01/07/16PRICE SENSITIVE
MSB Reinstatement to Official Quotation-MSB.AX
14/06/16PRICE SENSITIVE
MSB Update on Global Heart Failure Program-MSB.AX
14/06/16PRICE SENSITIVE
MSB Suspension from Official Quotation-MSB.AX
03/06/16PRICE SENSITIVE
MSB Trading Halt-MSB.AX
01/06/16PRICE SENSITIVE
MSB Mesoblast Receives $6.2m From Aus Govt For R&D-MSB.AX
20/05/16PRICE SENSITIVE
MSB Mesoblast Provides Q3 Financial Results and Corporate Update-MSB.AX
10/05/16PRICE SENSITIVE
MSB Third Quarter Financial Results On Form 6-K-MSB.AX
10/05/16PRICE SENSITIVE
MSB Appendix 4C - quarterly-MSB.AX
28/04/16PRICE SENSITIVE
MSB Mesoblast Cells Show Disease Modifying Effects on Knee OA
01/04/16PRICE SENSITIVE
MSB Key US Patent Granted For Treatment Of Rheumatoid Arthritis
24/03/16PRICE SENSITIVE
MSB GVHD Product Launched In Japan
24/02/16PRICE SENSITIVE
MSB Increased Survival Using MSB Cells In Children With aGVHD
22/02/16PRICE SENSITIVE
MSB Half Yearly Report and Accounts (including Appendix 4D)
17/02/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.49 		Change
-0.090(5.71%) 		Mkt cap ! $1.113B
Open High Low Value Volume
$1.58 $1.59 $1.47 $7.056M 4.697M

Buyers (Bids)

No. Vol. Price($)
2 3999 $1.48
 

Sellers (Offers)

Price($) Vol. No.
$1.49 46134 7
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.48 		  Change
-0.090 ( 5.55 %)
Open High Low Volume
$1.57 $1.57 $1.47 1111085
Last updated 15.59pm 21/11/2024 ?
MSB (ASX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.